# Can SS-31 (Elamipretide) improve mitochondrial function in Alzheimer's disease?

Canonical source: https://retacompare.com/research/can-ss-31-elamipretide-improve-mitochondrial-function-in-alzheimer-s-disease

Peptide Longevity Q&A · 2026-04-07


    Research indicates that SS-31 (Elamipretide) is a promising mitochondrial-targeted therapeutic in Alzheimer's disease, addressing mitochondrial dysfunction, which is a significant early contributor to the disease's development. This suggests potential benefits for mitochondrial function in aging-related conditions.

 What the research shows

The study discusses the multifactorial nature of Alzheimer's disease (AD), highlighting the role of mitochondrial dysfunction as a critical early factor in the disease's progression. SS-31 (Elamipretide) is mentioned as a mitochondrial-targeted therapeutic that may offer disease-modifying effects. The abstract emphasizes the importance of drug repurposing strategies to enhance therapeutic options for AD, particularly focusing on agents that target various pathological pathways including neuroinflammation, amyloid aggregation, and synaptic dysfunction. SS-31 is positioned among other promising mitochondrial therapeutics, suggesting its potential to improve mitochondrial function in the context of neurodegeneration.

 Why it matters for longevity

The implications of mitochondrial dysfunction extend beyond Alzheimer's disease, as mitochondrial health is crucial for overall cellular function and longevity. Mitochondria are the powerhouses of cells, and their dysfunction is associated with various age-related conditions. By targeting mitochondrial health, SS-31 (Elamipretide) may not only have a role in managing Alzheimer's disease but could also contribute to improved healthspan and longevity by mitigating the effects of aging on cellular energy production and reducing oxidative stress. This aligns with the growing interest in mitochondrial-targeted therapies as a strategy for enhancing longevity and addressing age-related decline.

 Key findings at a glance

Alzheimer's disease is characterized by complex pathophysiological processes including mitochondrial dysfunction.

SS-31 (Elamipretide) is identified as a mitochondrial-targeted therapeutic.

Mitochondrial dysfunction is noted as a significant early factor in the development of Alzheimer's disease.

Drug repurposing strategies are being explored to improve therapeutic options for Alzheimer's disease.

SS-31 is part of a broader category of agents targeting neurodegenerative processes.

 How SS-31 (Elamipretide) works (background)

SS-31 (Elamipretide) is designed to target mitochondria, enhancing their function and protecting against oxidative stress. By improving mitochondrial dynamics, SS-31 may help restore cellular energy levels and reduce the accumulation of reactive oxygen species, which are often elevated in neurodegenerative diseases. This mechanism is particularly relevant in Alzheimer's disease, where mitochondrial dysfunction contributes to neuronal damage and cognitive decline. The therapeutic approach of targeting mitochondria is gaining traction in research, as it addresses a root cause of many age-related diseases.

 Safety, caveats, and what we don't yet know

While SS-31 shows promise as a mitochondrial-targeted therapy, further research is necessary to fully understand its safety profile and efficacy across diverse populations. The current discussion is largely based on preclinical findings, and clinical trials are essential to establish its therapeutic potential in humans. Additionally, the abstract does not provide specific information on the outcomes of trials involving SS-31, nor does it detail any adverse effects that may arise from its use. Understanding these aspects is crucial for the integration of SS-31 into clinical practice.

 Bottom line

SS-31 (Elamipretide) may improve mitochondrial function, particularly in the context of Alzheimer's disease, suggesting potential benefits for aging-related conditions.

 Related questions

 Does SS-31 (Elamipretide) have potential for neuroprotection in aging?

Research indicates that SS-31 may offer neuroprotective effects by targeting mitochondrial dysfunction, which is critical in neurodegenerative diseases. This suggests its potential role in protecting neurons during aging.

 Can SS-31 (Elamipretide) be used alongside other therapies for Alzheimer's?

SS-31 is being explored as part of a drug repurposing strategy, which may allow it to be combined with other therapies targeting different pathways in Alzheimer's disease for enhanced efficacy.

 What are the implications of mitochondrial dysfunction in aging?

Mitochondrial dysfunction is linked to various age-related diseases, impacting cellular energy production and increasing oxidative stress. Targeting this dysfunction may improve healthspan and longevity.

 Source: PubMed · Ageing Res Rev · published 2026-04-07.

## Sources

- PubMed · Ageing Res Rev: https://pubmed.ncbi.nlm.nih.gov/41956136/